Crescendo Bioscience To Feature New Data On Vectra DA At 2014 ACR Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. MYGN, today announced that new data on Vectra® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15–19, 2014, in Boston, Massachusetts. "Vectra DA is a game changer for patients with RA because it provides clinical insights that help inform and improve clinical decisions for patients more effectively than tests like CRP or ESR," said Oscar Segurado, M.D., Chief Medical Officer of Crescendo. "The new clinical data being presented at ACR support the use of Vectra DA to assess RA disease activity and predict patient risk of joint damage." Oral Presentations Title: The multi-biomarker disease activity score as a predictor of radiographic progression in a registry of patients with rheumatoid arthritis. Presenter: Eric H. Sasso Date: November 19, 2014 9:30 a.m., Room 258 B, Presentation Number 2973 Title: Multi-biomarker disease activity score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state. Presenter: Nadine Defranoux Date: November 19, 2014 9:45 a.m., Room 258 B, Presentation Number 2974 Poster Presentations Title: Using the multi-biomarker disease activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment. Presenter: Ronald F. van Vollenhoven Date: November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 376 Title: In early rheumatoid arthritis, the multi-biomarker disease activity score at different time-points is predictive of subsequent radiographic progression. Presenter: Karen Hambardzumyan, Date: November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 364 Title: In early rheumatoid arthritis patients with non-response to methotrexate monotherapy the change in multi-biomarker disease activity score is differentially associated with subsequent response to non-biological versus biological therapy. Presenter: Karen Hambardzumyan Date: November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 367 Title: Preliminary assessment of a multi-biomarker disease activity test for axial spondyloarthritis. Presenter: Walter P. Maksymowych Date: November 18, 2014, 9:00-11:00 a.m. Exhibit Hall B, Presentation Number 2615